RxSight (RxSight) Additional Paid-In Capital : $767.7 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RxSight Additional Paid-In Capital?

RxSight's quarterly additional paid-in capital increased from Sep. 2023 ($747.0 Mil) to Dec. 2023 ($755.0 Mil) and increased from Dec. 2023 ($755.0 Mil) to Mar. 2024 ($767.7 Mil).

RxSight's annual additional paid-in capital increased from Dec. 2021 ($617.5 Mil) to Dec. 2022 ($636.0 Mil) and increased from Dec. 2022 ($636.0 Mil) to Dec. 2023 ($755.0 Mil).

RxSight Additional Paid-In Capital Historical Data

The historical data trend for RxSight's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight Additional Paid-In Capital Chart

RxSight Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

617.51

636.00

754.97

RxSight Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial													704.23	730.27	746.97	754.97	767.69

RxSight Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

RxSight Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of RxSight's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

RxSight (RxSight) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Columbia, Aliso Viejo, CA, USA, 92656

Website

https://www.rxsight.com

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

Executives

Ilya Goldshleger	officer: Chief Operating Officer	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg	officer: Chief Commercial Officer	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar	director	C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md	director, officer: See Remarks	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen	officer: Chief Financial Officer	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms	director	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano	director	110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116